Checchi Capital Advisers LLC increased its stake in AstraZeneca plc (NYSE:AZN) by 12.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,059 shares of the company’s stock after buying an additional 2,008 shares during the period. Checchi Capital Advisers LLC’s holdings in AstraZeneca were worth $730,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in AZN. Berman Capital Advisors LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $38,000. Pinnacle Bank bought a new position in AstraZeneca during the fourth quarter valued at approximately $38,000. Portfolio Solutions LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $40,000. Sontag Advisory LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $40,000. Finally, CNB Bank lifted its position in AstraZeneca by 245.0% during the fourth quarter. CNB Bank now owns 1,080 shares of the company’s stock valued at $41,000 after purchasing an additional 767 shares during the period. Institutional investors and hedge funds own 18.79% of the company’s stock.
A number of research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, April 8th. Deutsche Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, February 26th. Main First Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 19th. ValuEngine upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Finally, Pareto Securities upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, April 29th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average price target of $45.29.
AstraZeneca (NYSE:AZN) last posted its earnings results on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.02. The company had revenue of $5.47 billion during the quarter, compared to analysts’ expectations of $5.40 billion. AstraZeneca had a net margin of 10.75% and a return on equity of 37.91%. AstraZeneca’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $0.48 earnings per share. Equities research analysts expect that AstraZeneca plc will post 1.78 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by Rockland Register and is the sole property of of Rockland Register. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://rocklandregister.com/2019/06/14/checchi-capital-advisers-llc-has-730000-position-in-astrazeneca-plc-azn.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Trading Options- What is a Strangle?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.